Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Singapore Offers Public Funds To Bridge Valley Of Death, But Can It Last?  – BioMedical Asia

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - There is no dearth of research programs - the trouble is capital has evaporated and risk appetite is anorexic, BioMedical Asia speakers said in Singapore March 17

You may also be interested in...



Singapore, UK Award Infectious Disease Research Grants As Singapore Continues To Build Biomedical Research Base

SINGAPORE - Singapore and the United Kingdom have awarded SGD$4.5 million ($3.2 million) in grants covering six infectious disease research projects conducted jointly by Singapore and UK universities. The diseases include gastric flu, hepatitis B, dengue fever and tuberculosis

Singapore, UK Award Infectious Disease Research Grants As Singapore Continues To Build Biomedical Research Base

SINGAPORE - Singapore and the United Kingdom have awarded SGD$4.5 million ($3.2 million) in grants covering six infectious disease research projects conducted jointly by Singapore and UK universities. The diseases include gastric flu, hepatitis B, dengue fever and tuberculosis

PharmAsia News' Top Industry Trends Of 2009

As PharmAsia News wraps up its second year of publishing, we look back to some of the top trends and stories of 2009, as well as developing stories to keep an eye on in 2010

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel